
Bio-Techne to be Acquired by Merck KGaA for $73.00 Per Share
Bio-Techne CorporationDescription
What this story covers
Bio-Techne Corporation will become a wholly-owned subsidiary of Merck KGaA, Darmstadt, Germany, in an all-cash deal at $73.00 per share. The merger combines Bio-Techne's specialized protein analysis tools with Merck's global commercial scale and infrastructure.
Story snapshot
CompanyBio-Techne Corporation
TickerTECH
VariantStandard detailed
Duration4:03
Filing type8-K
PeriodQ4 2026
IndustryHealthcare & Pharmaceuticals
Accession0001999371-26-013527
Sources1
Full Story Script
Content not available for this story.